SMO and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, loss or pharmacological inhibition of SMO, an essential component of the Hh pathway, impairs LSC renewal, decreases the propagation of Bcr-Abl-driven CML, and reduces the growth of resistant CML [27].